Dr. Barbara White, Chief Medical Officer and Head of Research at Corbus Pharmaceuticals discusses Lenabasum, Corbus’ lead drug candidate that activates the often underutilized endocannabinoid system (ECS) to treat systemic sclerosis. Its Phase III trial recently completed treatment and is projected to release its data by the end of summer 2020.
Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Prior to joining Corbus, Dr. White was Senior Vice President and Head of R&D at Stiefel, a GSK company. Prior to her pharmaceutical career, Dr. White was Professor of Medicine and Vice-Chair for Research in the Department of Medicine at the University of Maryland School of Medicine. Her research has focused on T cells and immune-mediated mechanisms of lung fibrosis in scleroderma. Dr. White received her medical degree from the University of Pennsylvania School of Medicine and is board-certified in internal medicine, rheumatology and allergy/clinical immunology.